As of September 19, 2023, a group of four analysts have provided their 12-month price targets for QuidelOrtho. Their average price target stands at $117.75, with the highest estimate reaching $140.00 and the lowest at $85.00. It is worth noting that this current average has experienced a 6.56% increase compared to the previous average price target of $110.50.
These analysts are professionals in the banking and financial systems field, specializing in reporting on stocks or specific sectors. To gather information and formulate their ratings, they engage in various activities such as attending company conference calls and meetings, conducting research on company financial statements, and communicating with insiders. Their findings are then published as “analyst ratings” for stocks. It is customary for analysts to rate each stock once per quarter, providing valuable insights for investors.
QuidelOrtho Corporation
QDEL
Strong Buy
Updated on: 19/09/2023
Financial Health
Very Healthy
Debt to equity ratio: Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Neutral
QDEL Stock: Stable Performance with Negative Earnings Growth and Increased Revenue
QDEL stock had a relatively stable performance on September 19, 2023, with a slight decrease in value. The stock opened at the same price as the previous close, $75.04, and reached a high of $76.13 before settling at $75.04 again. The trading volume for the day was 12,554, which is significantly lower than the three-month average volume of 461,760.
The market capitalization of QDEL is $5.1 billion. However, the company has experienced negative earnings growth in the past year, with a decline of 42.28%. This trend continued into the current year, with earnings growth falling by 64.17%. The forecast for the next five years also predicts a decline in earnings growth, with a projected decrease of 23.00%.
Despite the negative earnings growth, QDEL has seen a significant increase in revenue growth over the past year, with a growth rate of 92.11%. This indicates that the company has been able to generate more revenue. The price-to-sales ratio for QDEL is 1.51, which suggests that the stock is trading at a relatively low valuation compared to its revenue.
The price-to-book ratio for QDEL is 1.02, indicating that the stock is trading close to its book value. This suggests that the market is valuing the company based on its assets and liabilities. The lack of executives displayed may indicate a recent change in leadership or a lack of available information.
QDEL’s corporate headquarters is located in San Diego, California. The company operates in the health technology sector, specifically in the medical specialties industry.
Looking ahead, QDEL’s next reporting date is scheduled for November 1, 2023. Analysts are forecasting earnings per share of $0.70 for the current quarter. In the previous year, QDEL reported annual revenue of $3.3 billion and a profit of $548.7 million. The net profit margin for the company is 16.82%.
In conclusion, QDEL stock had a relatively stable performance on September 19, 2023, with a slight decrease in value. The company has experienced negative earnings growth in recent years but has seen a significant increase in revenue. The stock is trading at a relatively low valuation compared to its revenue and book value. Investors should keep an eye on QDEL’s upcoming reporting date and the company’s ability to improve its earnings growth in the future.
QuidelOrtho Corp Stock Performance: Positive Price Forecasts and Analyst Consensus Support Growth Potential
On September 19, 2023, QuidelOrtho Corp’s stock performance was under scrutiny by investors and analysts. According to data sourced from CNN Money, the 12-month price forecasts provided by seven analysts had a median target of $110.00, with a high estimate of $168.00 and a low estimate of $81.00. This median estimate represented a significant increase of 45.29% from the last recorded price of $75.71.
The consensus among eight polled investment analysts was to buy stock in QuidelOrtho Corp. This rating has remained steady since December, indicating a continued positive sentiment towards the company’s prospects.
QuidelOrtho Corp reported earnings per share of $0.70 for the current quarter, with sales reaching $665.3 million. These figures provide a snapshot of the company’s recent financial performance and indicate its ability to generate revenue.
Investors and analysts eagerly await the reporting date of November 1st, as it will provide further insights into QuidelOrtho Corp’s financial health and potential for growth. This upcoming report will shed light on the company’s performance and may impact the stock’s future trajectory.
Considering the positive consensus among analysts and the optimistic price forecasts, it appears that QuidelOrtho Corp is positioned for growth. Investors may view this as an opportunity to capitalize on the potential increase in stock value. However, as with any investment, it is crucial to conduct thorough research and consider the potential risks before making any investment decisions.
In conclusion, QuidelOrtho Corp’s stock performance on September 19, 2023, was supported by positive price forecasts and a consensus among analysts to buy the stock. The upcoming financial report will provide further insights into the company’s performance and may influence its future trajectory. Investors should carefully consider the available information and conduct their due diligence before making any investment decisions.
Discussion about this post